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Abstract   
 
Background: Parkinson’s disease (PD) is a neurodegenerative disorder 
of unknown cause. The characteristic motor impairments of PD 
including resting tremor, rigidity, slowed movement, decreased 
dexterity, small handwriting, flexed posture, gait disorder, and 
imbalance predominantly arise from the loss of neurons in the 
substantia nigra region of the midbrain that produce the 
neurotransmitter dopamine. Dopamine replacement therapy provides 
temporary relief of motor symptoms, but chronic use leads to serious 
side effects and cannot prevent disease progression. This systematic 
review will focus upon gene therapy as a possible treatment for PD. 
 
 
 
Methods:  An exhaustive literature search was conducted in Medline, 
CINAHL, Web of Science, Google Scholar, and EBMRmultifile, using the 
search terms gene therapy and Parkinson’s disease in combination and 
alone as well as terms known to be synonymous. The search was 
limited to the English language, clinical trials and double-blind, 
randomized, controlled trials.  
 
 
Results: Two studies were reviewed based on the inclusion and 
exclusion criteria delineated in the methods section. Both studies were 
double-blind, randomized, controlled trials and utilized sham surgery 
for comparison. Marks et al showed adeno-associated type-2 vector 
(AAV2)-neurturin delivery in the putamen was not superior to sham 
surgery. LeWitt et al showed AAV2-glutamic acid decarboxylase (GAD) 
delivery in the subthalamic nucleus was superior to sham surgery.  
 
 
 
Conclusion: This systematic review shows gene therapy may prove to 
be a treatment option for patients with advanced Parkinson’s disease 
in the future. More research and development of gene therapy are 
needed.  
 
 
Keywords: Parkinson’s disease, gene therapy, adeno-associated type-2 
vector. 
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Gene Therapy for Parkinson’s Disease: A Systematic Review  
 
BACKGROUND  
 
Parkinson’s disease (PD) was named after Doctor James Parkinson, who 
first described the shaking palsy in 1817.1 In the United States, 50 000-60 000 cases 
of PD are diagnosed annually,2 adding to the one million people already living with 
the disease.3 PD is a neurodegenerative disorder, second only to Alzheimer’s 
disease;4 the complications from PD are the 14th leading cause of death in the 
United States.5 Worldwide, it is estimated that 4.1 million people suffer from PD,2 a 
number that is predicted to more than double to 8.7 million by 2030 6 
 PD poses only a slight reduction in life expectancy7 and most patients require 
therapy for at least 20 years. The combined direct and indirect financial burden of 
PD, including treatment, social security payments and lost income due to inability 
to work, is estimated to be $25 billion per year in the United States.3 This estimate 
is set to dramatically increase due to rising health care costs and the growing 
senior population. 
 The underlying cause of PD is unknown. PD is clinically characterized by the 
cardinal features of resting tremor, bradykinesia, rigidity, and postural instability8, 
9 (cumulatively termed parkinsonism)8. Pathologically, PD is characterized by the 
progressive loss of midbrain neurons in the substantia nigra pars compacta.4 These 
neurons project to the putamen and caudate (striatum) and release the 
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neurotransmitter dopamine (DA).10 Symptoms of parkinsonism are evidenced 
when more than half of the DA nerve terminals in the striatum have 
degenerated.10  
 DA cannot cross the blood brain barrier, so L-3,4-dihydroxyphenylalanine (L-
dopa) is utilized.11 L–amino acid decarboxylase (AADC) converts L-dopa (drug 
name levodopa) to DA in the central and peripheral nervous systems.12 This drug 
therapy provides substantial relief during the early stages of PD, although 
levodopa-induced motor response fluctuations and dyskinesias (involuntary 
movements) are often seen with long-term treatment.13 Further, chronic levodopa 
treatment is linked to motor complications and does not control for disabling 
features such as falling and dementia.14 Adverse events present in more than 80% 
of patients within the first ten years of levodopa medication; some patients 
demonstrate signs of dyskinesias during the first year.15 DA agonists, amantadine, 
catechol O-methyltransferase (COMT) inhibitors and other drugs can reduce 
fluctuations in plasma L-dopa levels, which improve mobility and reduce 
dyskinesias. Yet, these drugs tend to fail after several years16 and side effects of DA 
agonists include impulse control disorders.17 
Deep brain stimulation (DBS) delivers electrical impulses to a specific 
region, or regions of the brain and has become the “gold standard” surgical 
treatment for PD.11 Loss of striatal dopaminergic innervation leads to overactivity 
in the internal segment of the globus pallidus and subthalamic nucleus. DBS works 
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by seizing the overactivity in the subthalamic nucleus and has proven to be more 
effective than pharmacotherapy.14 However, serious adverse events are more 
common in patients receiving DBS, including fatal intracerebral hemorrhage.14 In 
addition, similar to dopaminergic therapy, DBS can fail to treat the parkinsonian 
features of freezing of gait, imbalance, dysphagia, cognitive and psychiatric 
disorders and speech difficulties and does not prevent neurodegeneration.15  
Nonetheless, the success of deep brain stimulation (DBS) by diminishing 
the activity of the subthalamic nucleus inspired researchers to further explore 
methods to modulate the basal ganglia circuitry (caudate, putamen, globus 
pallidus, substantia nigra and subthalmic nucleus).14 High doses of oral levodopa  
precipitate negative side effects by acting upon the entire body and brain in 
uncontrolled concentration gradients with related extreme swings in extracellular 
DA levels. These insights led researchers to employ viral vector delivery of genes 
for local and continuous therapy into the basal ganglia.2 Gene therapy theoretically 
permits lower therapeutic doses with localized effects, thereby reducing adverse 
side effects, while providing diffuse, long-term expression of a therapeutic 
protein.16-19 
Gene therapy treatment potentially serves as a single intervention resulting 
in stable and long-term20 expression of a therapeutic molecule in the brain. 
Reduction in the medication and its associated adverse side effects might mitigate 
the financial burden of PD treatment.12 The success of gene therapy treatments 
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tested in in-vitro and animal models of PD paved the way for their continued 
investigation in clinical trials. During phase I clinical trials, researchers test a new 
treatment in a small group of people to evaluate safety, safe dosage range, and 
identify possible side effects.21 In phase II clinical trials, the treatment is provided 
to a larger group to further evaluate safety and determine effectiveness.21 For 
phase III clinical trials, treatment is given to large groups in order to confirm 
effectiveness, record effects, compare to past treatments, and collect information; 
which would allow for the treatment to be used safely.21 Phase IV clinical trials are 
performed after the treatment has been marketed in order to gather data on the 
treatment’s effect in various populations and possible adverse side effects linked to 
long-term use.21 
Three unique gene therapy treatments for PD have advanced to clinical 
trials. Each gene therapy treatment utilizes a virus, which has been genetically 
engineered to act as a vehicle through which molecules are introduced to the 
central nervous system. One approach uses the lentivirus to supply the three 
enzymes required for DA synthesis: tyrosine hydroxylase (TH), L-amino acid 
decarboxylase (AADC) and GTP-cyclohydrolase-1 (GCH1).12, 22 On April 16th, 2012, 
Oxford Biomedica announced completion of their phase I/II clinical trial of 
Prosavin, a lentivirus encoding TH, AADC and GCH1. This triple enzyme 
approach promotes DA expression within the striatal GABAergic neurons in a 
continuous manner. Oxford Biomedica reported in a press release that Prosavin-
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treated PD patients experienced an average motor function improvement of 30%, 
which is a statistically significant improvement in the unified Parkinson’s disease 
rating scale (UPDRS) motor scores.23 The published results of this phase I/II trial 
are anxiously awaited.  
Another gene therapy method employs the adeno-associated virus serotype 
2 vector (AAV2), which has been genetically engineered to deliver novel genes into 
both dividing and non-dividing cells, which are then expressed by the body’s 
cellular machinery.24-29 The AAV2 vector does not cause an inflammatory reaction, 
demonstrates an excellent safety and efficacy profile in clinical trials, and provides 
long-term transgene expression without inducing dyskinesias.30 AAV2-neurturin 
and AAV2-glutamic acid decarboxylase (GAD) are two gene therapy treatments for 
PD, which have been investigated in clinical trials. 
The loss of nigrostriatal dopaminergic neurons alters striato-pallidal 
circuitry so that decreased gamma-aminobutyric acid (GABA) input renders the 
subthalamic nucleus disinhibited, which disrupts output to the basal ganglia 
circuitry.24 Glutamic acid decarboxylase (GAD) is the rate-limiting enzyme for 
GABA production; delivering GAD to the subthalamic nucleus would replenish 
GABA transmission within the nucleus and normalize output to key targets in the 
basal ganglia.15,24 Exciting data from preclinical and open-label, phase I trials 
demonstrated AAV2-GAD gene therapy improved motor function,31 was 
neuroprotective, and slowed degeneration of dopaminergic neurons.32 
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Neurturin belongs to the glial cell derived neurotrophic factor (GDNF) 
family33 and is a potent neurotrophic survival factor for several populations of 
central and peripheral neurons.34 Neurturin encodes for the tyrosine kinase 
receptor and enhances survival and function of DA neurons in animal models of 
PD.35-38AAV2-neurturin gene therapy shows potential for delaying degeneration of 
dopaminergic neurons in PD.39-41 An open-label, phase I trial of intraputaminal 
AAV2-neurturin in PD patients demonstrated improved motor function and 
treatment safety.42 This systematic review will assess the efficacy of AAV2 gene 
therapy treatment for PD.  
METHODS 
 An exhaustive literature search without restrictions was conducted in 
Medline, CINAHL, Web of Science, Google Scholar, and EBMRmultifile using the 
search terms Parkinson’s disease and gene therapy in combination and alone. 
Scientific terms that were synonymous with these terms, including PD, Parkinson 
disease, Parkinson's, primary parkinsonism, paralysis agitans, adeno-associated 
type-2 vector, AAV2-GAD and AAV2-neurturin, were searched to prevent the 
omission of any relevant articles.  
Inclusion criteria were then set for articles published in the English 
language, clinical trials (human subjects) and double-blind, randomized, 
controlled trials. Phase I open-labeled clinical trials, perspectives and research 
proposals were excluded, duplicates were removed, and titles and abstracts were 
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screened for relevancy. The references of selected articles were screened for the 
presence of any articles not produced in the original literature search.  
 The articles reviewed were critically appraised using GRADE,43 an approach 
to evaluate quality of evidence. Each article was placed into a category based on 
the quality of evidence: high, medium, low and very low. Study limitations for 
randomized trials included lack of allocation concealment, lack of blinding, 
incomplete accounting for patients and outcome events, selective outcome 
reporting bias and stopping trial early for benefit and use of invalidated outcome 
measures.41 There were no study limitations in Marks et al.44or LeWitt et al.15  
RESULTS 
The initial search identified 419 articles. Based upon inclusion and exclusion 
criteria, two double-blind, randomized, controlled trials assessing gene therapy for 
PD were deemed appropriate for this systematic review. See Figure 1. Both studies 
were phase II clinical trials using sham surgery as their control, and used change 
from baseline in off-medication UPDRS motor scores as their primary outcome 
measures. The UPDRS motor score (part 3) ranges from 0 to 108, with higher 
scores indicating more severe disease. Clinically significant differences in the 
UPDRS motor score are estimated to be 2.5 points for minimal, 5.2 for moderate, 
and 10.8 for large effects. 45  
Marks et al.44 found the efficacy of AAV2-neurturin gene delivery in the 
putamen was not superior to sham surgery when assessed using the UPDRS motor 
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score at 12 months (p=0.91). Results were statistically significant at 18 months, 
though modest (p=0.023). LeWitt et al.15 found the efficacy of AAV2-GAD gene 
therapy in the subthalamic nucleus was superior to sham surgery when assessed by 
UPDRS at 6 months to an extremely significant degree (p<.0001). 
Marks et al.44 conducted a multicenter, double-blind, phase II, sham-
surgery controlled trial to assess AAV2-neurturin gene therapy for PD. Enrolled in 
the study were men and women of any ethnicity, 35-75 years of age, with PD 
according to the UK Brain Bank Criteria, and with disease duration of at least five 
years. Inclusion criteria were levodopa responsiveness and levodopa-induced 
motor complications unsatisfactorily controlled with medical therapy; at least two 
hours per day of off time (poor motor function), score of at least 30 on the motor 
section (part 3) of UPDRS in the off state, and stable doses of anti-parkinsonian 
drugs for a minimum of one month prior to enrollment. The protocol was 
approved by the institutional review boards at each of the participating 
institutions as well as the recombinant DNA advisory committee of the National 
Institutes of Health (NIH). Exclusion criteria were atypical or secondary PD; mini-
mental state exam of 26 or less; previous neurosurgical treatment for PD; and 
significant medical, psychiatric, or laboratory abnormalities. Between December 
2006 and November 2008, 58 eligible patients from nine sites in the United States 
participated. There were no notable differences in demographics and baseline 
characteristics between groups. Of the 38 patients randomly assigned to AAV2-
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neurturin and 20 to sham surgery (2:1), 37 and 20 were included in primary 
analysis, respectively. One patient in the AAV2-neurturin group suffered a 
myocardial infarction and did not complete the study. All patients and study 
personnel, with the exception of the neurosurgical team, were blinded to 
treatment assignment.44 
Stereotactic surgery was performed via neuroimaging to plan injection 
trajectories. After participants were anesthetized with propofol sedation, a 
treatment kit was opened, which determined intervention assignments. Patients 
assigned to active treatment received administration of AAV2-neurturin to the 
putamen, bilaterally through frontal burr holes. Patients assigned to sham surgery 
underwent a similar procedure, with the exception that the burr holes did not 
penetrate the inner table of the skull and intracranial injections of AAV2-neurturin 
were not performed.44  
Serious adverse events occurred in 13 of the 38 patients treated with AAV2-
neurturin and four of the 20 patients assigned to sham surgery. Three patients in 
the AAV2-neurturin group and two in the control group developed tumors. Two 
patients in the AAV2-neurturin group died (one myocardial infarction and one 
pulmonary embolism); however, the events were judged as unrelated to AAV2-
neurturin. Using quantitative PCR assay, biopsied tumors occurring in the AAV2-
neurturin group (one glioblastoma, one esophageal adenocarcinoma and one 
adenocarcinoma of the prostate) were not found to contain AAV2-neurturin. In 
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addition, upon further examination, the glioblastoma had been present on MRI 
prior to study entry.44 
The primary endpoint was change from baseline to 12 months in the motor 
subscore of the UPDRS in the practically defined off state. From baseline to 12 
months, the AAV2-neurturin group decreased 7.21 points, while the sham surgery 
decreased 6.91 points, for an average difference of 0.31 points; a statistically 
insignificant amount (p=0.91). Between baseline and 18 months, eight patients in 
the AAV2-neurturin group were followed up and showed an average decrease of 
11.96 points, while the six patients in sham surgery that were followed up 
decreased by an average of 4.34 points, for an average difference of 7.61 points 
between the groups; a modest but significant benefit (p=0.023). Multiple 
secondary endpoints (UPDRS part 1 and 2, home diary assessments, timed walking 
test, Purdue pegboard test, dyskinesia rating scale, PDQ-39 index score, physical 
health composite score, severity of illness and global improvement) favored AAV2-
neurturin at 12 and 18 months, but none favored the sham surgery at either time 
point. Still, these data are not the primary endpoint, and the sample size was 
small.44 
LeWitt et al.15 assessed AAV2-GAD gene therapy for PD by conducting a 
double-blind, phase II, randomized, sham-surgery controlled trial, which took 
place at seven centers in the United States between November 2008 and May 2010. 
All patients had progressive, levodopa-responsive PD as defined by UK Parkinson’s 
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Disease Society criteria.46 Levodopa and other PD drugs were allowed if no change 
in dose or drug type was made for at least one month prior to enrollment. An 
overnight off-medication UPDRS 47 part 3 score of 25 or more was required. 
Further inclusion criteria were age 30-75 years, symptom duration of PD for at 
least five years, and levodopa responsiveness for at least 12 months. Exclusion 
criteria were previous brain surgery, use of DA receptor-blocking drugs, focal 
neurological deficits, abnormal cranial magnetic resonance imaging (MRI), or 
cognitive impairment by Mattis dementia rating scale less than 130. 18 F-
fluorodeoxyglucose positron emission tomography (PET) scans were required for 
diagnostic confirmation of PD and excluded patients with atypical parkinsonism or 
indeterminate patterns.31, 48 Study protocols and consent forms were approved by 
institutional review boards at each participating institution.15 
A statistician and a programmer -each with no further role in the study - 
created the computer-generated random treatment assignment. Twenty-three 
patients were randomly assigned to sham surgery and 22 to AAV2-GAD infusions 
in the subthalamic nucleus; of those, 21 and 16, respectively, were analyzed. Six 
patients from the AAV2-GAD group and two patients from the sham surgery group 
were excluded from analysis because they did not receive the allocated 
intervention. This was due to unilateral infusion, catheter malfunction, missed 
surgical target or catheter misplacement, or unblinding. Patients, caregivers and 
investigators were masked to treatment assignment. For sham-surgery 
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participants, the neurosurgeon and operating room team simulated a bilateral 
stereotaxic procedure identical to the AAV2-GAD group. Sham-surgery patients 
received partial-thickness burr holes after a stereotaxic frame was placed. 
Simulation included sounds of microelectrode recording; pumps and catheters 
infusing normal saline into the burr hole sites were used identically as for patients 
treated with AAV2-GAD. For participants receiving AAV2-GAD, a frame-based 
targeting and intraoperative microelectrode recording specified the boundaries of 
the subthalamic nucleus,49, 50 and microelectrode centering within the nucleus 
defined by measurement and fluoroscopy. A catheter was placed and attached to 
the pump, and an infusion of vector genomes AAV-GAD65 and AAV-GAD67 was 
delivered at .23 uL/min over 2.5 hours in the subthalamic nucleus on both sides of 
the brain. Following infusions, a fine-cut head computed tomography (CT) scan 
showed catheter tip locations. A neurosurgeon with expertise on the subthalamic 
nucleus—who remained masked to study data—determined if the catheter tip 
location was in the subthalamic nucleus. In one participant, the postoperative CT 
showed that both catheter tips had been unintentionally placed in the same 
subthalamic nucleus, so this patient was unmasked after surgery and removed 
from group analysis.15  
One serious adverse event - bowel obstruction - occurred within six months 
of surgery in an AAV2-GAD participant, but was not attributed to the treatment or 
surgical procedure, and fully resolved. Other adverse events were mild or 
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moderate and considered likely related to surgery; the most common being 
headache (7 patients in the AAV2-neurturin group versus 2 in the sham surgery 
group) and nausea (6 versus 2).15 
One movement-disorder specialist who was masked to treatment allocation 
judged UPDRS motor examinations and brief parkinsonism rating scales (BPRS) at 
baseline, and at one, three and six months following treatment. All randomly 
assigned patients were followed up and assessed through the six-month trial. 
Authors defined a clinically meaningful response to be more than a 9.0-point 
reduction in UPDRS motor score, which corresponds to a moderate to large 
clinically important difference reported in an analysis for PD treatments.45 The 
primary endpoint was change from baseline to six months in UPDRS motor score. 
AAV2-GAD treatment led to a reduction of 8.1 points (p<0.0001) in off-medication 
UPDRS motor score at the study endpoint of six months, compared to a reduction 
of 4.7 points (p=0.003) for sham surgery.15 See Table 1. 
DISCUSSION 
The demonstrated safety, tolerability and efficacy of certain gene therapy 
techniques for PD are quite exciting, and these results justify continued 
investigation and development. Numerous questions remain about what 
constitutes optimal gene therapy for PD, and which area of the brain would be 
best served by such treatment. Oxford Biomedica23 delivered gene therapy to the 
striatum and reported both clinically and statistically significant improvements in 
UPDRS motor scores. Marks et al.44 discovered that AAV2-neurturin delivered 
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to the putamen was not beneficial at 12 months but demonstrated a modest 
improvement at 18 months. It’s possible that the putamen is not an ideal target site 
for AAV2-neurturin. The benefit of neurturin depends upon transport of the 
protein (or DNA) from the striatum to the substantia nigra. The degeneration of 
the nigrostriatal pathway of PD patients could have impaired transport of 
neurturin, blunting its therapeutic benefit. LeWitt et al.15 delivered AAV2-GAD to 
the subthalamic nucleus and published statistically significant improvement in 
UPDRS motor scores.  
While each of these studies reports improvement in motor function by 
delivering gene therapy to one specific area of the brain, PD affects multiple 
regions of the brain. There is little scientific basis for reasoning that localized 
delivery of therapeutic proteins, genes or enzymes would significantly and/or 
clinically improve the non-dopaminergic features of PD.51 Even so, the 
neurological dysfunction brought about by progressive DA degeneration is a major 
pathological feature of PD. AAV2-neurturin and AAV2-GAD exhibit potential to 
restore DA function without the dyskinesias from levodopa therapy or the adverse 
events of DBS.52 
Gene therapy treatments for PD are in the beginning phases of clinical 
research: phase II clinical trials serve as proof of concept in a smaller population. 
The next step will be phase III/IV clinical trials aiming to demonstrate robust 
results in larger populations, determine if any long-term adverse side effects exist, 
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and better assess if gene therapy for PD is a practical option for general clinical 
use. More in-depth research may elucidate the required predictability of the 
immediate and long-term actions of each therapeutic protein involved gene 
therapy treatment. Better understanding, combined with refined and reliable 
technique, more sophisticated mechanics and possibly a blend of optimal gene 
therapies - may one day prove to be an effective, alternative treatment for PD. In 
clinical practice, patients wishing to participate in clinical trials of gene therapy for 
PD would potentially receive such treatment. At present, gene therapy for PD 
provides additional insight into the disease and offers hope for an alternative 
treatment. It may take decades before gene therapy treatment modalities become 
readily available for patients. A summary of findings is presented in Table 1. 
Gene therapy treatments for PD are currently being investigated in patients 
with advanced PD, who are likely to be an older subset of the population. Gene 
therapy needs to be delivered to specific regions of the brain via surgery warrants 
extreme caution. Risks from surgery are often augmented in an elderly population. 
For Marks et al.,44 most of the adverse events in both the AAV2-neurturin and 
sham surgery groups were associated with surgery. For LeWitt et al.,15 the adverse 
events were mainly headache and nausea and were attributed to intracranial 
surgery in both the AAV2-GAD group and the sham surgery group. No infection, 
reaction to anesthesia, seizure, stroke, coma, or memory loss occurred in either 
study and other serious adverse events were not attributed to the gene therapy or 
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the surgical procedure. Yet, these serious adverse events remain a concern when 
performing intracranial surgery, especially in an older population.   
Both articles are phase II clinical trials, which are the earlier stage of the 
drug development process. The absence of obvious safety concerns in these phase 
II trials is heartening but not a definitive proof of safety, and follow-up of larger 
numbers of patients over many years is required. Immune responses to gene 
therapy remain unknown. Continually expressing a therapeutic gene, protein or 
enzyme within the brain via a viral vector remains a novel idea with unpredictable 
short-term and long-term effects. Once gene therapy is injected it is impossible to 
control or reverse gene expression. The tumors occurring in the AAV2-neurturin 
group in Marks et al.44 were not thought to be related to the treatment, yet the 
potential for a trophic factor to induce and/or accelerate tumor growth is possible, 
and patients should remain in follow-up for longer periods of time.  
Double-blind, randomized, controlled studies provide a high level of 
evidence and according to GRADE 43, there were no major deficiencies in study 
design found. Major deficiencies include very large loss to follow-up, inadequacy of 
allocation concealment, and/or an unblinded study with subjective outcomes 
highly susceptible to bias.41 Nonetheless, study limitations were found. Each study 
used relatively few patients, which can lead to sparse and imprecise data (wide 
confidence intervals).41  Yet, it is expected that small, phase II trials are likely 
underpowered for some of the clinical outcomes.   
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Both studies received funding from drug companies responsible for 
producing the investigated gene therapy, which introduces the risk of bias. For 
LeWitt et al.15 Neurologix took part in the study design, data interpretation and 
writing of the report, but did not contribute to data collection or data analysis.15 
For Marks et al.,44 Ceregene funded the study and was responsible for supplying 
AAV2-neurturin, collecting data, and monitoring the clinical and statistical 
analysis. The authors were responsible for study design, data analysis, data 
interpretation, writing of the report and submittal for publication. Variability in 
results was seen between Marks et al.44 and LeWitt et al.15. This may have been 
anticipated since the investigators were employing unique gene therapy 
treatments into separate regions of the brain.  
Lastly, the authors made no mention of cost. CT, MRI and PET imaging 
combined with pre-, intra- and post-operation care, surgery, a hospital stay and 
the price of a newly marketed drug could prove to be financially prohibitive for 
patients, and insurance companies are slow to cover the cost of new therapies.  
Recommendations for further study include multiple, phase I-IV clinical 
trials, with an increased number of participants, longer-term follow up for adverse 
events and funding by a government agency. See Table 2.  
CONCLUSIONS 
 The continued research and development of gene therapy treatments for 
PD are warranted, and may offer an alternative to traditional, subpar 
 
 
 
 
 
 
 
 
 
 
 
 
     
      
23 
pharmacological or surgical treatment. Intraputaminal AAV2-neurturin is not 
superior to sham surgery when assessed using the UPDRS motor score at 12 
months, but showed improvement at 18 months.44 AAV2-GAD in the subthalamic 
nucleus showed significantly greater improvement from baseline in UPDRS motor 
scores compared with sham surgery over six months.15 
Gene therapy remains a relatively unpredictable and novel treatment 
modality, and these trials are still in the early stages of research. For these reasons, 
more studies, involving hundreds of patients with long-term follow up are needed 
to confirm that gene therapy for PD is safe and effective. The modest benefit of 
AAV2-neurturin in the putamin, the published efficacy of AAV2-GAD in the 
subthalamic nucleus 15 and reported results of Prosavin therapy 22 offer a glimpse 
of gene therapy's current potential and the future possibilities.  
 Marks et al44 LeWitt et al15 
 
Study Type 
 
Therapy Study  
Double blind, randomized, sham surgery controlled, 
multicentre trial 
 
 
Therapy Study 
  Double blind, randomized, sham surgery controlled, 
multicentre trial 
 
 Population 
 
Men and women, age 35–75, with idiopathic, 
levodopa-responsive PD according to the UK Brain 
Bank Criteria with disease duration at least 5 years 
 
Men and women, age 30–75, with progressive, 
levodopa-responsive PD defined by the UK PD 
Society criteria with disease duration at least 5 years 
 
 
 
UPDRS motor score change: baseline to 12 months 
 
 
 UPDRS motor score change: baseline to 6 months 
AAV2-neurturin therapy 
 
-7.19 points* 
Sham Surgery 
 
-6.95 pointsℑ 
AAV2-GAD therapy 
 
-8.1 points^ 
Sham Surgery 
 
-4.7 pointsφ 
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Table 1. Summary of Findings 
 
UPDRS=unified Parkinson’s disease rating scale. Range 0-108, higher number indicates more severe impairment. Marks et al44, data are in least squares mean (SE, 95% Confidence Intervals) * 1.56, -10.34 to -4.09.  ℑ 2.12, -11.16 to -2.66. A difference of -0.31 (2.63, -5.58 to 4.97) p=0.91  δ 1.87, -15.8 to -8.7.  Ω 2.48, -9.52 to 0.75. A difference of -7.61 (3.16, -14.1 to -1.13) p=0.023   ^SD1.7, 23.1%; p<0.0001.  φ  SD1.5, 12.7%; p=0.003 
 
                  
 
 
 
 
Table 2. Quality of Evidence 
 
QUALITY ASSESSMENT 
 
Study Study Design Limitatio
ns 
Publication 
Bias 
Inconsistenc
y 
Indirectness Imprecision Sampl
e Size 
Quality 
 
 
Marks 
et al44 
 
Therapy 
Study – 
Double blind, 
randomized 
controlled 
trial 
 
 
 
No study 
limitation
s 
 
 
Ceregene 
funded study 
 
 
No 
inconsistenci
es 
 
 
No areas of 
indirectness  
 
 
No serious 
imprecision
∇ 
 
 
53 
 
 
High 
Primary 
Endpoint 
Results  
 
 
 
 
UPDRS motor score change: baseline to 18 months 
 
 
UPDRS motor score change: baseline to 12 months 
 
AAV2-neurturin therapy 
 
 -11.96 pointsδ 
 
Sham Surgery 
 
 -4.34 pointsΩ 
 
AAV2-GAD therapy 
 
To be published in 
separate paper 
 
Sham Surgery 
 
To be published in 
separate paper 
 
Conclusions 
 
Intraputaminal AAV2-neurturin is not superior to 
sham surgery when assessed using the UPDRS motor 
score at 12 months. Modest, but significant motor 
improvement was seen at 18 months. 
 
AAV2-GAD in the subthalamic nucleus showed 
significantly greater improvement from baseline in 
UPDRS motor scores compared with sham surgery 
over six months. 
 
      
25 
 
 
LeWitt 
et al15 
 
Therapy 
Study – 
Double blind, 
randomized 
controlled 
trial 
 
 
 
No study 
limitation
s 
 
 
Neurologix 
funded study 
 
 
No 
inconsistenci
es 
 
 
No area of 
indirectness  
 
 
No serious 
imprecision
δ 
 
 
45 
 
 
High 
 
Overall 
quality of 
evidence 
 
CONCLUSION:  Both studies offered high quality evidence. However, further research 
is likely  
to impact the confidence in these studies’ estimates and may change the estimates. 
 
 
 
Moderat
e 
 ∇ Small sample size, but met predetermined n=51 for 90% power to detect a difference of 10 (SD 10) points between groups 
 δ  Small sample size, but met predetermined n=13 per group to achieve 80% power to detect effect size of 1.19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Search Methodology 
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